
In today’s briefing:
- SoCar: A Partial Tender Offer by SOQRI
- Digging Into the Early Full Rollout of NPS’s Reference Portfolio Play
- What We Need to Know About the Korean Commercial Act Amendment Right Now
- Hoban Group Purchases LS Corp Shares – Is This a Hanjin Kal 2.0?
- Seoul Guarantee Insurance IPO Trading – KDIC Stake Overhang Remains, Yield Might Help
- Sam Chun Dang Pharm (000250 KS): Oral Semaglutide Trial Begins; Global Expansion of Eylea Biosimilar

SoCar: A Partial Tender Offer by SOQRI
- After the market close on 13 March, it was reported that SOQRI Co will be doing a partial tender offer public offering of 171,429 common shares of Socar.
- The tender offer period is from 14 March to 2 April. The tender offer price is 17,500 won which is a 21% premium to current price.
- Socar’s founder Lee Jae-Woong is pushing for a tender offer to solidify the control of Socar from Lotte Rental which has recently been purchased by Affinity Equity Partners.
Digging Into the Early Full Rollout of NPS’s Reference Portfolio Play
- The street suspects NPS is fast-tracking its reference portfolio in local equities, not just rebalancing to cover last year’s underweight in its Q1 2025 adjustment.
- The passive-to-active shift is on—starting with enhanced passive, then an early ramp into event-driven and high-conviction active plays.
- We traders should expect outsized swings in leaders and restructuring plays as NPS flows amplify moves.
What We Need to Know About the Korean Commercial Act Amendment Right Now
- Lee Bok-hyun, FSS Chairman, unexpectedly reversed his stance and now opposes Choi’s veto on the amendment, pushing for shareholder protection and adjustments in subordinate regs instead.
- From a short-term trading angle, traders will focus on stocks with high volatility potential related to auditor appointments rather than the extension of directors’ fiduciary duties to shareholders.
- Large-Cap banks and non-bank stocks, with low controlling stakes and high foreign ownership, are likely to see significant short-term trading impact.
Hoban Group Purchases LS Corp Shares – Is This a Hanjin Kal 2.0?
- In this insight, we discuss a new catalyst on the share price of LS Corp (006260 KS) which is the purchase of its shares by the Hoban Group.
- Hoban Group has recently purchased shares of LS Corp. Although the exact percentage of shares has yet to be made public, it is estimated to be less than 3%.
- LS Corp could improve shareholder returns. Plus, the ongoing litigation between Taihan Electric Wire and LS Cable may be the real reason why Hoban decided to invest in LS Corp.
Seoul Guarantee Insurance IPO Trading – KDIC Stake Overhang Remains, Yield Might Help
- Seoul Guarantee Insurance (031210 KS) raised around US$125m in its Korean IPO.
- Seoul Guarantee Insurance (SGI) is a guarantee insurance firm operating predominantly in Korea.
- We have looked at the firm’s past performance and discussed our thoughts on valuation. In this note, we talk about the trading dynamics.
Sam Chun Dang Pharm (000250 KS): Oral Semaglutide Trial Begins; Global Expansion of Eylea Biosimilar
- Sam Chun Dang Pharm (000250 KS) has commenced bioequivalence study of oral semaglutide. Difference in technology should allow the drug to enter the market as early as 2026.
- Last December, the company has partnered with Fresenius Kabi for the global commercialization of its Eylea biosimilar in the U.S. and several countries in Latin America.
- Sam Chun Dang Pharma shares rallied 113% since its early December lows. With continued progress of high-value generics, we remain upbeat on the name.